SOP for Receiving Updates on Pharmacopoeias (IP, USP, Ph. Eur.)

In short: This example SOP shows how a Quality Control department can stay current with pharmacopoeial changes: who watches which pharmacopoeia, how new editions and supplements are obtained, how affected specifications and methods are updated before the effective date, and how superseded copies are withdrawn. Each pharmacopoeia has its own publication cycle, so the SOP should track the official publisher’s schedule.

This is an illustrative template. Adapt roles, forms and timelines to your own quality system and to the pharmacopoeias named in your marketing authorisations.

1. Objective

To define how Quality Control receives, reviews and implements updates (new editions, supplements, revisions and corrections) of the pharmacopoeias used at the site.

2. Scope

This SOP applies to the Quality Control department of the manufacturing facility and covers the Indian Pharmacopoeia (IP), United States Pharmacopeia–National Formulary (USP–NF), British Pharmacopoeia (BP) and European Pharmacopoeia (Ph. Eur.), plus any other pharmacopoeia named in a product’s registration.

3. Responsibility

• Authorised designee, QC: monitors official sources, requests procurement, reviews updates and raises change controls.
• Regulatory Affairs / Corporate QA: procures publications or subscriptions and confirms which pharmacopoeia and edition each product’s registration follows.
• Head of QC or designee: ensures implementation of this SOP.
• Quality Assurance: controls withdrawal of superseded copies.

4. Procedure

4.1 Monitoring official sources

The QC designee checks the publishers’ official pages at a defined frequency (example in-house criterion: monthly) and records the check.

Do not rely on third-party summaries for effective dates. Use the pharmacopoeia’s own notice.

4.2 Procurement

1. On finding a new edition, supplement or issue, QC informs Regulatory Affairs / Corporate QA to procure it (print, online licence or subscription).
2. Regulatory Affairs confirms which products are affected and whether the registration requires the new text.

4.3 Receipt and control of copies

1. Log the new pharmacopoeia or update (title, edition or issue, publication date, effective date, copy number, location) in the pharmacopoeia register.
2. Update the list of current pharmacopoeias.
3. Mark the superseded copy “Superseded” with the date and hand it to QA. Retain superseded copies, or an archived electronic version, as long as needed to reconstruct the standard that applied when a batch was tested. Batch-related records must be kept at least 1 year after the expiry date of the respective product batch (EU GMP Part I, Chapter 4, section 4.11; 21 CFR 211.180(a)), longer if local law or the marketing authorisation requires.
4. Online access does not remove the need for control: record the access date and the version consulted.

4.4 Review and impact assessment

1. QC reviews the changes in monographs and general chapters used at the site (raw materials, finished products, excipients, reagents, methods).
2. For each affected item, record: the change, affected specifications, test methods, standard test procedures and reference standards, and whether a method verification or revalidation is needed.
3. Raise a change control for specification and method changes (see Change control).
4. Where the product’s registration cites a specific edition, Regulatory Affairs decides whether a variation or notification to the authority is needed. A change of the compendial standard does not by itself change a registered specification.

4.5 Implementation before the effective date

1. Revise affected specifications, standard test procedures and worksheets, and train analysts, so they are in force on or before the official effective date.
2. For supplements, Regulatory Affairs sends the affected monographs to QC for updating.
3. Update document control records as per SOP for documentation control procedure.

5. Training

• Trainer: Head of Quality Control.
• Trainees: QC chemists and section heads.

6. Distribution

• Controlled copy 1: Head of QA
• Controlled copy 2: Head of QC
• Master copy: Head of QA

7. Annexures

Pharmacopoeia register and update impact assessment form (to be created by the site).

8. Revision history

Frequently asked questions

Which pharmacopoeia must my product follow?

The one named in the product’s registration or licence, and in India, the standards required under the Drugs and Cosmetics Act. Regulatory Affairs should confirm this per product.

When must a new monograph be applied?

From the official or implementation date stated by the publisher, not the publication date.

Is an online subscription enough?

It can be, if access is controlled and the version consulted is recorded.

References

• Indian Pharmacopoeia Commission, Indian Pharmacopoeia 2026 (10th edition) and addenda/amendment lists: https://www.ipc.gov.in
• USP, Publication & Comment Schedule (USP–NF issues, publication and official dates): https://www.usp.org/usp-nf/development-process/publication-comment-schedule
• EDQM, European Pharmacopoeia 12th/13th Edition publication schedule and implementation notices: https://www.edqm.eu
• European Commission, EudraLex Volume 4, EU GMP Part I, Chapter 4 Documentation, section 4.11.
• US FDA, 21 CFR 211.180(a).